EPISODE · Apr 20, 2023 · 2 MIN
FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma
from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) · host U.S. Food and Drug Administration, Center for Drug Evaluation and Research
Lsten to a soundcast of the March 22, 2023 FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma.
Embed this episode
Ready to play
FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma
0:00
2:30
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)?
This episode is 2 minutes long.
When was this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode published?
This episode was published on April 20, 2023.
Can I download this FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!